Skip to Content

"Gastric Pacemaker" Fakes Fullness as You Eat

Implant could be an alternative to gastric bypass surgery.

An implant intended as a less drastic alternative to stomach stapling or stomach bypass surgery for the morbidly obese is now being sold in Europe. The device senses when a person is eating and generates a premature sensation of fullness by stimulating nerves that curl around the stomach.

Full tank: This implant could help people lose weight by detecting when they eat and stimulating nerves to make them feel full.

The implant, developed by Intrapace, a company based in Mountain View California, is available in Germany, Spain, and the U.K.; the first implantations are scheduled to be carried out later this week. In trials involving 65 patients, the company says, the device led to an average weight loss of 22 percent after one year, with some patients losing as much as 38 percent of their body weight. These results have not yet been published.

The implant, called Abiliti, is also equipped with an accelerometer that shows a physician how much exercise the patient is getting. Data from the device can be uploaded to a computer wirelessly.

Abiliti is about the size of a pacemaker and is designed to be implanted within the abdominal cavity but outside the stomach through minimally invasive laparoscopic surgery. Two leads connect it to the stomach—one for sensing and the other for stimulating. A sensor is passed through the stomach wall; this detects when food enters. A stimulating electrode that’s been attached to stretch receptor nerves outside the stomach then sends sensations of fullness to the brain via the vagus nerve.

By detecting when food starts to enter the stomach, the implant is able to stimulate nerves prematurely and simulate sensations of being full before the stomach actually starts to fill, says Chuck Brynelsen, president and CEO of Intrapace.

Gastric neurostimulation has been proposed previously as a way of tackling obesity, but the success of such devices so far has been poor. A similar device developed by Transneuronix, a company in New Jersey, also used vagus-nerve stimulation. But after the company was bought by medical device giant Medtronic, trials with hundreds of patients showed no clear benefit, and the technology appears to have been scrapped.

Devices that stimulate the vagus nerve continuously can lead to habituation, in which the nerve adapts to the stimulus and essentially learns to ignore it.

“What’s unique about the Abiliti device, and what attracted me to it, is that it’s got the capacity for intelligent sensing,” says Abeezar Sarela a bariatric surgeon at the University of Leeds School of Medicine, in the U.K., who plans to start offering the device to his patients.

At a cost of around $21,000 for the device and surgery, Abiliti is slightly more expensive than a stomach bypass and nearly twice the price of a gastric band, says Sarela. However, it should have none of the side effects, such as nausea or vomiting can be caused by structurally altering the stomach, he says.

The only notable new side effect is a slight risk of infection due to the incision in the stomach, says Sarela. But even so, while Abiliti will be particularly suited to some patients, Sarela doesn’t see it replacing stomach stapling or bypasses for the vast majority of cases, at least not for the foreseeable future. “These will remain the workhorses of bariatric surgery,” he says.

Keep Reading

Most Popular

open sourcing language models concept
open sourcing language models concept

Meta has built a massive new language AI—and it’s giving it away for free

Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.